{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:17:02Z","timestamp":1778606222035,"version":"3.51.4"},"reference-count":138,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.rpsm.2018.02.005","type":"journal-article","created":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T03:25:28Z","timestamp":1523071528000},"page":"151-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Patr\u00f3n de uso de clozapina en Espa\u00f1a. Variabilidad e infraprescripci\u00f3n"],"prefix":"10.1016","volume":"12","author":[{"given":"Francisco Javier","family":"Sanz-Fuentenebro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Juan Uriarte","family":"Uriarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Bonet Dalmau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Molina Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miquel","family":"Bernardo Arroyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpsm.2018.02.005_bib0700","first-page":"i375","article-title":"\u201cSchizophrenia\u201d does not exist","volume":"352","author":"Van Os","year":"2016","journal-title":"BMJ."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0705","series-title":"Delirio: historia. Cl\u00ednica. Metateor\u00eda","author":"Berrios","year":"1996"},{"key":"10.1016\/j.rpsm.2018.02.005_bib0710","unstructured":"National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management Clinical guideline [publicado 12 Feb 2014; consultado 29 Mar 2018]. Disponible en: nice.org.uk\/guidance\/cg178"},{"key":"10.1016\/j.rpsm.2018.02.005_bib0715","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1192\/bjp.bp.116.182683","article-title":"Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?","volume":"209","author":"Murray","year":"2016","journal-title":"Br J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0720","article-title":"Uso de antipsic\u00f3ticos en la psicosis. Alcance, limitaciones y alternativas","author":"Inchauspe","year":"2017","journal-title":"Rev la Asoc Espa\u00f1ola Neuropsiquiatr\u00eda."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0725","first-page":"8","article-title":"Antipsychotic medication during the critical period following remission from first-episode psychosis: Less is more","author":"Mcgorry","year":"2013","journal-title":"JAMA Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0730","article-title":"Long-term outcome following early dose-reduction of antipsychotics in remitted first episode psychosis","author":"Wunderink","year":"2015","journal-title":"Schizophr Bull."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0735","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/pds.2213","article-title":"National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom","volume":"21","author":"Prah","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0740","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0745","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch Gen Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0750","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0755","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch Gen Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0760","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0765","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: A network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0770","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0775","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1017\/S0033291709005455","article-title":"Second-generation antipsychotics for schizophrenia: Can we resolve the conflict?","volume":"39","author":"Leucht","year":"2009","journal-title":"Psychol Med."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0780","first-page":"649","article-title":"The F CATIE and CUtLASS studies in schizophrenia: Results and implications for clinicians","volume":"23","author":"Naber","year":"2009","journal-title":"CNS Drugs."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0785","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0790","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). UTILIZACI\u00d3N DE ANTIPSIC\u00d3TICOS EN ESPA\u00d1A (1992-2006) [consultado 28 Mar 2018]. Disponible en: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/observatorio\/docs\/antipsicoticos.pdf"},{"key":"10.1016\/j.rpsm.2018.02.005_bib0795","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1176\/ps.2009.60.9.1175","article-title":"Off-label use of antipsychotic medications in the department of Veterans Affairs health care system","volume":"60","author":"Leslie","year":"2009","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0800","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/ajp.156.7.990","article-title":"Evidence of clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials","volume":"156","author":"Wahlbeck","year":"1999","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0805","first-page":"CD000966","article-title":"Newer atypical antipsychotic medication versus clozapine for schizophrenia","author":"Tuunainen","year":"2000","journal-title":"Cochrane database Syst Rev."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0810","doi-asserted-by":"crossref","unstructured":"Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res [Internet]. 2002;56:1\u201310.","DOI":"10.1016\/S0920-9964(01)00212-2"},{"key":"10.1016\/j.rpsm.2018.02.005_bib0815","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0820","first-page":"CD006633","article-title":"Clozapine versus other atypical antipsychotics for schizophrenia","author":"Asenjo Lobos","year":"2010","journal-title":"Cochrane database Syst Rev."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0825","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1017\/S1092852912000806","article-title":"Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: Evidence from a systematic review and meta-analyses","volume":"18","author":"Souza","year":"2013","journal-title":"CNS Spectr."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0830","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamapsychiatry.2015.2966","article-title":"The role of clozapine in treatment-resistant schizophrenia","volume":"73","author":"Kane","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.rpsm.2018.02.005_bib0835","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/bmj.327.7405.33","article-title":"The case for knowledge translation: Shortening the journey from evidence to effect","volume":"327","author":"Davis","year":"2003","journal-title":"Br Med J."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0840","doi-asserted-by":"crossref","unstructured":"Murray RM, Kerwin R, Taylor D, et al. SW Lewis, L Davies, PB Jones, TRE Barnes, RM Lewis SW, Davies L, Jones PB, Barnes TRE, Murray RM, Kerwin R, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess. 2006;10:iii-iv, ix-xi, 1-165.","DOI":"10.3310\/hta10170"},{"key":"10.1016\/j.rpsm.2018.02.005_bib0845","first-page":"1","author":"Lobos","year":"2014","journal-title":"Funders Group Clozapine versus other atypical antipsychotics for schizophrenia."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0850","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/09638230410001700916","article-title":"Consumers\u2019 views of electroconvulsive therapy: A qualitative analysis","volume":"13","author":"Rose","year":"2004","journal-title":"J Ment Heal."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0855","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.38881.382755.2F","article-title":"Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study","volume":"333","author":"Tiihonen","year":"2006","journal-title":"BMJ."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0860","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","article-title":"A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia","volume":"168","author":"Tiihonen","year":"2011","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0865","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia","author":"Tiihonen","year":"2017","journal-title":"JAMA psychiatry"},{"key":"10.1016\/j.rpsm.2018.02.005_bib0870","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1371\/journal.pone.0083539","article-title":"Clozapine prescribing in a Canadian outpatient population","volume":"8","author":"Alessi-Severini","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0875","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.schres.2013.07.003","article-title":"Randomized trial of clozapine vs. risperidone in treatment-na\u00efve first-episode schizophrenia: Results after one year","volume":"149","author":"Sanz-Fuentenebro","year":"2013","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0880","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0269881108093588","article-title":"Outcomes for schizophrenia patients with clozapine treatment: How good does it get?","volume":"23","author":"Wheeler a","year":"2009","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0885","doi-asserted-by":"crossref","unstructured":"Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology [Internet]. 1997;8:671\u20137.","DOI":"10.1097\/00001648-199711000-00014"},{"key":"10.1016\/j.rpsm.2018.02.005_bib0890","doi-asserted-by":"crossref","unstructured":"Duggan A, Warner J, Knapp M, Kerwin R. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br J Psychiatry [Internet]. 2003;182:505\u20138.","DOI":"10.1192\/bjp.182.6.505"},{"key":"10.1016\/j.rpsm.2018.02.005_bib0895","doi-asserted-by":"crossref","unstructured":"Meltzer HY, Baldessarini RJ. Reducing the risk for suicide in schizophrenia and affective disorders. J Clin Psychiatry [Internet]. 2003;64:1122\u20139.","DOI":"10.4088\/JCP.v64n0920"},{"key":"10.1016\/j.rpsm.2018.02.005_bib0900","doi-asserted-by":"crossref","unstructured":"Alphs L, Anand R, Islam MZ, Meltzer HY, Kane JM, Krishnan R, et al. The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. Schizophr Bull [Internet]. 2004;30:577\u201386.","DOI":"10.1093\/oxfordjournals.schbul.a007102"},{"key":"10.1016\/j.rpsm.2018.02.005_bib0905","unstructured":"FDA. \u201cClozaril\u201d Prescribing information [consultado 29 Mar 2018]. Disponible en: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/019758s062lbl.pdf"},{"key":"10.1016\/j.rpsm.2018.02.005_bib0910","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/archpsyc.63.6.622","article-title":"Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Krakowski","year":"2006","journal-title":"Arch Gen Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0915","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10673229909017206","article-title":"Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?","volume":"6","author":"Green","year":"1999","journal-title":"Harv Rev Psychiatry [Internet]."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0920","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000104886","article-title":"Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders","volume":"13","author":"San","year":"2007","journal-title":"Eur Addict Res."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0925","first-page":"11","article-title":"Clozapine use in dual diagnosis patients","volume":"1","author":"Mar\u00edn-Mayor","year":"2014","journal-title":"J Clin Med Res Updat."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0930","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jad.2014.04.020","article-title":"Rapid clozapine titration in treatment-refractory bipolar disorder","volume":"166","author":"Ifteni","year":"2014","journal-title":"J Affect Disord."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0935","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bdi.12018","article-title":"Real-world effectiveness of clozapine in patients with bipolar disorder: Results from a 2-year mirror-image study","volume":"14","author":"Nielsen","year":"2012","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0940","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.20051","article-title":"Long-term outcome of clozapine use for psychosis in parkinsonian patients","volume":"19","author":"Fernandez","year":"2004","journal-title":"Mov Disord."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0945","first-page":"9","article-title":"Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia","volume":"60 Suppl 1","author":"Lieberman","year":"1999","journal-title":"J Clin Psychiatry [Internet]"},{"key":"10.1016\/j.rpsm.2018.02.005_bib0950","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0955","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","article-title":"Management of treatment resistance in schizophrenia","volume":"50","author":"Conley","year":"2001","journal-title":"Biol Psychiatry [Internet]."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0960","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1192\/bjp.bp.110.088690","article-title":"Clozapine: Dangerous orphan or neglected friend?","volume":"198","author":"Farooq","year":"2011","journal-title":"Br J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0965","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1176\/appi.ajp.2015.15030332","article-title":"Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia","volume":"173","author":"Stroup","year":"2016","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0970","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.4088\/JCP.16com10797","article-title":"How many treatments before clozapine? Medication choices across the spectrum of treatment resistance in schizophrenia","volume":"77","author":"Weiden","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0975","first-page":"11","article-title":"Esquizofrenia \u201cresistente\u201d. Conceptos confusos y tratamientos esperanzadores","volume":"8","author":"Sanz Fuentenebro","year":"2001","journal-title":"Psiquiatr Biol."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0980","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2012.02.013","article-title":"Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation","volume":"197","author":"Suzuki","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0985","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4088\/JCP.13m08351","article-title":"Clozapine and risperidone in moderately refractory schizophrenia: A 6-month randomized double-blind comparison","volume":"77","author":"Schooler","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0990","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib0995","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: Systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1000","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2007.11.033","article-title":"World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia","volume":"100","author":"Tandon","year":"2008","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1005","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.pnpbp.2007.01.004","article-title":"Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia","volume":"31","author":"Wehmeier","year":"2007","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1010","first-page":"1","article-title":"Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia","volume":"29","author":"Schneider","year":"2014","journal-title":"Eur Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1015","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/acps.12621","article-title":"Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: A real-world observational study","volume":"134","author":"Vanasse","year":"2016","journal-title":"Acta Psychiatr Scand."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1020","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","article-title":"An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis","volume":"72","author":"Agid","year":"2011","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12888-016-1177-y","article-title":"Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review","volume":"17","author":"Gillespie","year":"2017","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1030","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1035","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function","volume":"75","author":"Demjaha","year":"2014","journal-title":"Biol Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1040","doi-asserted-by":"crossref","first-page":"30144","DOI":"10.3390\/ijms161226228","article-title":"Alterations of dopamine D2 receptors and related receptor-interacting proteins in schizophrenia: The pivotal position of dopamine supersensitivity psychosis in treatment-resistant schizophrenia","volume":"16","author":"Oda","year":"2015","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1045","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.psychres.2015.02.021","article-title":"Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia","volume":"227","author":"Suzuki","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1050","doi-asserted-by":"crossref","DOI":"10.3371\/1935-1232.10.3.163","article-title":"A guide to the management of clozapine-related tolerability and safety concerns","author":"Citrome","year":"2016","journal-title":"Clin Schizophr Relat Psychoses."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.rpsm.2011.11.003","article-title":"Clozapine and agranulocitosis in Spain: Do we have a safer population? A 5-year hematologic follow-up","volume":"5","author":"Pons","year":"2012","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1060","article-title":"Increase in white cell and neutrophil counts during the first eighteen weeks of treatment with clozapine in patients admitted to a long-term psychiatric care inpatient unit","author":"Capllonch","year":"2016","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1065","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4088\/JCP.11r06977","article-title":"Beyond white blood cell monitoring: Screening in the initial phase of clozapine therapy","volume":"73","author":"Cohen","year":"2012","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1070","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4088\/JCP.12com07964","article-title":"Monitoring clozapine adverse effects calls for the integration of protocol and good clinical practice","volume":"73","author":"Bak","year":"2012","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1075","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1080","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jpsychires.2013.05.034","article-title":"Mortality in persons with mental disorders is substantially overestimated using inpatient psychiatric diagnoses","volume":"47","author":"Crump","year":"2013","journal-title":"J Psychiatr Res."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1085","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/schbul\/sbu120","article-title":"The effect of clozapine on premature mortality: An assessment of clinical monitoring and other potential confounders","volume":"41","author":"Hayes","year":"2015","journal-title":"Schizophr Bull."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1090","first-page":"110","article-title":"Current status of clozapine in the United States","volume":"24","author":"Kelly","year":"2012","journal-title":"Shanghai Arch psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3371\/CSRP.LAWY.012513","article-title":"Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Qu\u00e9bec","volume":"7","author":"Latimer","year":"2013","journal-title":"Clin Schizophr Relat Psychoses."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1100","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1176\/appi.ps.002022012","article-title":"Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia","volume":"64","author":"G\u00f6ren","year":"2013","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1105","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1176\/appi.ps.54.11.1453","article-title":"Underuse of evidence-based treatments in psychiatry","volume":"54","author":"Fayek","year":"2003","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1176\/appi.ps.56.3.320","article-title":"Comparison of clozapine use in Maryland and in Victoria, Australia","volume":"56","author":"Conley","year":"2005","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4088\/JCP.v64n0107","article-title":"Prior antipsychotic prescribing in patients currently receiving clozapine: A case note review","volume":"64","author":"Taylor","year":"2003","journal-title":"J Clin Psychiatry [Internet]."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/oxfordjournals.schbul.a006924","article-title":"Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region","volume":"28","author":"Weissman","year":"2002","journal-title":"Schizophr Bull."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.psc.2007.04.008","article-title":"Real-world antipsychotic treatment practices","volume":"30","author":"Moore","year":"2007","journal-title":"Psychiatr Clin North Am."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1139\/jpn.100055","article-title":"Clozapine: A distinct, poorly understood and under-used molecule","volume":"35","author":"Joober","year":"2010","journal-title":"J Psychiatry Neurosci."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1135","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1176\/appi.ps.201300180","article-title":"Geographic and clinical variation in clozapine use in the United States","volume":"65","author":"Stroup","year":"2014","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1140","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.euroneuro.2012.03.003","article-title":"Geographical and temporal variations in clozapine prescription for schizophrenia","volume":"22","author":"Nielsen","year":"2012","journal-title":"Eur Neuropsychopharmacol."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1145","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3109\/00048674.2011.607426","article-title":"Clozapine use in schizophrenia: Findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009","volume":"45","author":"Xiang","year":"2011","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.rpsm.2018.02.005_bib1150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3371\/CSRP.4.1.4","article-title":"Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world","volume":"4","author":"Mortimer","year":"2010","journal-title":"Clin Schizophr Relat Psychoses."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1155","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.euroneuro.2014.01.014","article-title":"Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales","volume":"24","author":"Patel","year":"2014","journal-title":"Eur Neuropsychopharmacol."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ajp.2015.09.013","article-title":"Prescription practices and attitude of psychiatrists towards clozapine: A survey of psychiatrists from India","volume":"18","author":"Grover","year":"2015","journal-title":"Asian J Psychiatr."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1165","first-page":"1","article-title":"International trends in clozapine use: A study in 17 countries","author":"Bachmann","year":"2017","journal-title":"Acta Psychiatr Scand."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ps.201500324","article-title":"Clozapine for schizophrenia: State variation in evidence-based practice","volume":"67","author":"Olfson","year":"2016","journal-title":"Psychiatr Serv [Internet]."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1175","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-244X-14-102","article-title":"Clozapine: A review of clinical practice guidelines and prescribing trends","volume":"14","author":"Warnez","year":"2014","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1180","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ps.201500324","article-title":"Clozapine for schizophrenia: State variation in evidence-based practice","volume":"67","author":"Olfson","year":"2016","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1185","unstructured":"National Institute for Health and Care Excellence (NICE). Schizophrenia Clinical guideline [CG1] Published date: December 2002 [consultado 29 Mar 2018]. https:\/\/www.nice.org.uk\/guidance\/cg1"},{"key":"10.1016\/j.rpsm.2018.02.005_bib1190","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1192\/pb.bp.106.013144","article-title":"Clozapine: National review of postcode prescribing","volume":"31","author":"Downs","year":"2007","journal-title":"Psychiatr Bull."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1195","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/schbul\/sbp130","article-title":"The schizophrenia patient outcomes research team (PORT): Updated treatment recommendations 2009","volume":"36","author":"Kreyenbuhl","year":"2010","journal-title":"Schizophr Bull."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1200","first-page":"135","article-title":"Pharmacotherapy for treatment-resistant","volume":"7","author":"Mcilwain","year":"2011","journal-title":"Neuropsychiatr Dis Treat."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1205","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.rpsm.2013.01.001","article-title":"Emerging guidelines for the use of antipsychotic polypharmacy","volume":"6","author":"Stahl","year":"2013","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1210","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1345\/aph.1K662","article-title":"Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand","volume":"42","author":"Wheeler","year":"2008","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1215","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: Study of antipsychotic treatment prior to clozapine initiation","volume":"201","author":"Howes","year":"2012","journal-title":"Br J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1220","unstructured":"Royal College of Psychiatrists. Report of the Second Round of the National Audit of Schizophrenia (NAS). 2014 [consultado 29 Mar 2018]. Disponible en: http:\/\/www.rcpsych.ac.uk\/pdf\/FINAL_report_for_the_second_round_of_the_National_Audit_of_Schizophrenia-8.10.14v2.pdf"},{"key":"10.1016\/j.rpsm.2018.02.005_bib1225","doi-asserted-by":"crossref","first-page":"e1447","DOI":"10.4088\/JCP.15m10063","article-title":"Clozapine use in first-episode psychosis: The Singapore Early Psychosis Intervention Programme (EPIP) perspective","volume":"77","author":"Tang","year":"2016","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1230","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0042-116947","article-title":"Time to initiation of clozapine treatment in children and adolescents with early-onset schizophrenia","volume":"49","author":"Trinczek","year":"2016","journal-title":"Pharmacopsychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1235","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/YIC.0000000000000086","article-title":"Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia","volume":"30","author":"\u00dc\u00e7ok","year":"2015","journal-title":"Int Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1240","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1176\/appi.ps.57.1.133","article-title":"Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia","volume":"57","author":"Mallinger","year":"2006","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1245","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1176\/appi.ajp.160.10.1817","article-title":"Racial disparity in the use of atypical antipsychotic medications among veterans","volume":"160","author":"Copeland","year":"2003","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1250","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.4088\/JCP.v67n0911","article-title":"Clozapine utilization and outcomes by race in a public mental health system: 1994-2000","volume":"67","author":"Kelly","year":"2006","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1255","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ps.201100435","article-title":"Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees","volume":"63","author":"Manuel","year":"2012","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1265","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.rpsm.2017.06.002","article-title":"Concentrations in plasma clozapine levels in schizophrenic and schizoaffective patients","volume":"10","author":"Iglesias Garc\u00eda","year":"2017","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1270","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JCP.0000000000000478","article-title":"Clozapine underutilization in the treatment of schizophrenia. How can clozapine prescription rates be improved?","volume":"36","author":"Bogers","year":"2016","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1275","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12888-015-0578-7","article-title":"An evaluation of variation in published estimates of schizophrenia prevalence from 19902013: A systematic literature review","volume":"15","author":"Simeone","year":"2015","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1280","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12882-017-0456-2","article-title":"Costs of care at the end of life among elderly patients with chronic kidney disease: Patterns and predictors in a nationwide cohort study","volume":"18","author":"Chen","year":"2017","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1285","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.adaj.2016.11.020","article-title":"Antibiotic prescribing by general dentists in the United States, 2013","volume":"148","author":"Roberts","year":"2017","journal-title":"J Am Dent Assoc."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1290","article-title":"Pattern of electroconvulsive therapy use in Spain: Proposals for an optimal practice and equitable access","author":"Sanz-Fuentenebro","year":"2016","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1295","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hup.821","article-title":"Clinical correlates of clozapine prescription for schizophrenia in China","volume":"22","author":"Xiang","year":"2007","journal-title":"Hum Psychopharmacol."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1300","doi-asserted-by":"crossref","first-page":"99","DOI":"10.9758\/cpn.2012.10.2.99","article-title":"Use of clozapine for the treatment of schizophrenia: Findings of the 2006 research on the China psychotropic prescription studies","volume":"10","author":"Si","year":"2012","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1305","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.schres.2015.07.048","article-title":"Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002-2012)","volume":"168","author":"Li","year":"2015","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1310","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40263-016-0311-1","article-title":"Worldwide differences in regulations of clozapine use","volume":"30","author":"Nielsen","year":"2016","journal-title":"CNS Drugs."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1315","first-page":"4","article-title":"Antipsychotics in the treatment of schizophrenia: an overview","volume":"72 Suppl 1","author":"Tandon","year":"2011","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1320","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1176\/ps.2008.59.5.547","article-title":"Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006","volume":"59","author":"Alessi-Severini","year":"2008","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1325","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/070674371105601009","article-title":"The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009","volume":"56","author":"Pringsheim","year":"2011","journal-title":"Can J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1330","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pds.2082","article-title":"Increasing off-label use of antipsychotic medications in the United States, 1995-2008","volume":"20","author":"Alexander","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1335","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00228-004-0868-3","article-title":"Antipsychotic prescribing pattern among Italian general practitioners: A population-based study during the years 1999-2002","volume":"61","author":"Trifir\u00f2","year":"2005","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1340","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2165\/00023210-200418130-00002","article-title":"Starting clozapine in the community: A UK perspective","volume":"18","author":"O\u2019Brien","year":"2004","journal-title":"CNS Drugs [Internet]."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1345","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/0269881108100320","article-title":"Psychiatrists\u2019 attitude towards and knowledge of clozapine treatment","volume":"24","author":"Nielsen","year":"2010","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1350","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1192\/bjp.bp.112.114777","article-title":"Clinician hesitation prior to clozapine initiation: Is it justifiable?","volume":"201","author":"Patel","year":"2012","journal-title":"Br J Psychiatry."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1395","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/2045125314566808","article-title":"Clozapine prescribing in the UK: Views and experience of consultant psychiatrists","volume":"5","author":"Tungaraza","year":"2015","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.rpsm.2018.02.005_bib1400","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1176\/appi.ps.201500493","article-title":"An initiative to improve clozapine prescribing in New York State","volume":"67","author":"Carruthers","year":"2016","journal-title":"Psychiatr Serv."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1365","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jama.282.9.867","article-title":"Impact of formal continuing medical education: do conferences, workshops, rounds, and Dother traditional continuing education activities change physician behavior or health care outcomes?","volume":"282","author":"Davis","year":"1999","journal-title":"JAMA [Internet]."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1370","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.rpsm.2015.09.001","article-title":"Estrategias para la implementaci\u00f3n de gu\u00edas cl\u00ednicas de trastornos comunes de salud mental","volume":"9","author":"Moreno","year":"2016","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1375","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1478-7547-9-6","article-title":"Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia","volume":"9","author":"Phanthunane","year":"2011","journal-title":"Cost Eff Resour Alloc."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1380","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11632020-000000000-00000","article-title":"Comparative effectiveness of atypical antipsychotics in schizophrenia: What have real-world trials taught us?","volume":"26","author":"Attard","year":"2012","journal-title":"CNS Drugs."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1385","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2146\/ajhp110461","article-title":"Development of an outpatient pharmacist-managed clozapine clinic","volume":"69","author":"Williams","year":"2012","journal-title":"Am J Health Syst Pharm."},{"key":"10.1016\/j.rpsm.2018.02.005_bib1390","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1176\/appi.ap.11090159","article-title":"Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation","volume":"37","author":"Freudenreich","year":"2013","journal-title":"Acad Psychiatry."}],"container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989118300156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989118300156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:33:03Z","timestamp":1761823983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1888989118300156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":138,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1888989118300156"],"URL":"https:\/\/doi.org\/10.1016\/j.rpsm.2018.02.005","relation":{},"ISSN":["1888-9891"],"issn-type":[{"value":"1888-9891","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patr\u00f3n de uso de clozapina en Espa\u00f1a. Variabilidad e infraprescripci\u00f3n","name":"articletitle","label":"Article Title"},{"value":"Revista de Psiquiatr\u00eda  y Salud Mental","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpsm.2018.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 SEP y SEPB. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}